Veriheal

APRIL 11, 2022

You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

AUGUST 24, 2021

Thus, there is a great need to develop new and effective therapeutics for treating patients. Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease and decline rather than only addressing the symptoms.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

SEPTEMBER 6, 2021

For instance, it is very effective in reducing nausea and increasing appetite among chemotherapy patients. Similarly, it is also used in combination with traditional opioid painkillers, which enables patients to reduce the dosage and frequency of opioids significantly and imparts greater pain relief. Key Topics Covered: 1 Preface.

Chronic Pain 86

Chronic Pain Research and Development Clinical Trials Epilepsy 86

The Cannigma

MARCH 7, 2022

When CBN was studied without barbiturates (prescription sedative medications typically used for epilepsy), the combination of CBN and THC produced greater sedation together than either cannabinoid alone. What can the current clinical trials tell us?

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Bonaventure University and George Washington University School of Medicine. . School: University of Maryland.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

CannaTech

SEPTEMBER 16, 2018

Doctors have remained integral parts of a patient’s cannabis journey through what is known as the Access to Cannabis for Medical Purposes Regulation (ACMPR) act. These guidelines outline a list of qualifying conditions that patients must possess in order to legally obtain medical cannabis. Shedding Stigma and Promoting Patient Access.

Education 66

Education Medicine Clinical Trials Patients 66

Cannabis Law Report

NOVEMBER 24, 2019

Finding more information and committee details. Severe treatment-resistant epilepsy. People have the right to be involved in discussions and make informed decisions about their care, as described in your care. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. Recommendations.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Patients using warfarin need to have their blood INR level tested after adding THC-containing cannabis to their regimen. How Do CBD Drug Interactions Occur? topiramate.

CBD 98

CBD THC Conditions Medicine 98

MMJ Recs

DECEMBER 22, 2023

Public discourse became more nuanced, with patients and advocacy groups championing the cause of medical marijuana as a legitimate and effective treatment option. Surveys and polls consistently show a majority of Americans supporting medical marijuana, reflecting a more informed and open-minded approach to its potential benefits.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Law Report

JANUARY 13, 2020

We are proud of the positive impact this medicine has already had on thousands of patients and believe that this past year provides a compelling foundation for continued success in 2020,” said Justin Gover, GW’s Chief Executive Officer. Execute NHIE clinical program utilizing an intravenous formulation of cannabidiol. Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

Most official studies conducted on CBD for anxiety conclude with tentative support for CBD as an appropriate treatment for anxiety, but researchers in virtually every case suggest that more information is needed on an individual level to determine the appropriateness of using cannabis to treat anxiety.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

The Cannigma

AUGUST 26, 2021

The country legalized medical cannabis in 2016, but patients in the country have long criticized the program as too restrictive, and access to cannabis-based medicines remains behind that of many other legal cannabis jurisdictions. A doctor who applies to the TGA on behalf of a patient must provide a clinical justification.

Legalization 52

Legalization Access Medicine Clinical Trials 52

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

The Joint Blog

FEBRUARY 24, 2021

This is not the first medicinal trial of its kind. Cannabis and CBD oils have often been used to reduce the effects of epilepsy and several other neurological issues, so why not Parkinson’s? Though trialing is relatively new and there is no clear scientific evidence as of yet, anecdotal evidence from patients is looking positive.

Treatment 55

Treatment Clinical Trials Collective Patients 55

Cannabis Law Report

DECEMBER 7, 2021

This trend is also observed in the pediatric population, where MCs are authorized in children for refractory epilepsy, especially in Dravet syndrome and Lennox-Gastaut syndrome 2. If these attempts failed, the information as available was utilized to include the data when applicable. Adverse mental events.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

APRIL 10, 2019

MP Philippa Whitford (representing Central Ayrshire ), a doctor, called for more support for clinical trials so that doctors will be more willing to prescribe medical cannabis products: “That is quite scary for doctors, particularly as if it is an unlicensed drug, they have to sign a form to say that they accept personal liability.

Clinical Trials 51

Clinical Trials Epilepsy Medicine Research and Development 51

Greencamp

AUGUST 16, 2018

Because of the very rapid progression of ALS in the majority of patients, understanding how cannabis could help in the alleviation of symptoms is incredibly important for ALS sufferers. Both upper and lower motor neurons suffer severe damage in ALS patients. As few as 10% of ALS patients live longer than 10 years after being diagnosed.

Strains 94

Strains Cannabinoids Research and Development Indica 94

Cannabis Law Report

JANUARY 5, 2022

This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. 4 [link].

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

JULY 15, 2019

Law 33/2018 set the framework for the regulation of the use of cannabis-based medicinal products, preparations and substances that would effectively allow Portuguese patients to access medical cannabis What really has changed during the last year? July 18 marks the first anniversary of the Portuguese medical cannabis law. For now, at least.

Medicine 40

Medicine Clinical Trials Patients Access 40

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions.[1]. Patients using warfarin need to have their blood INR level tested after adding THC-containing cannabis to their regimen. How Do CBD Drug Interactions Occur? topiramate.

CBD 52

CBD THC Conditions Medicine 52

CannaMD

AUGUST 8, 2020

For more information, see: What Is Hemp & Why Does It Matter? ). Designed to treat seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome , Epidiolex is a purified (> 98% oil-based) CBD extract administered via oral spray. CBD is also a favorite among insomnia patients.

CBD 99

CBD DEA Research and Development Hemp 99

The Cannigma

JUNE 15, 2021

Some healthcare professionals are already encouraged by what is known, much of it anecdotal accounts from patients in their practices. The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

FEBRUARY 3, 2022

Patients suffering from chronic diseases, like Parkinson’s, Alzheimer’s, cancer, and many neurological disorders, are administered cannabis. CBD oils have various health benefits in treating medical disorders like epilepsy, anxiety, cancer, acne, diabetes, and others. Clinical Trials of Cannabis Are Still on Going.

Indica 52

Indica Oil Legalization Research and Development 52

Cannabis Law Report

SEPTEMBER 28, 2021

DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This Epilepsy – Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.

Epilepsy 52

Epilepsy Clinical Trials Research and Development Pharmaceutical 52

Cannabis Law Report

JUNE 1, 2021

As we prepare for a potential world-class launch of Vicineum, I strongly believe that these leaders will not only bring diverse and invaluable expertise to our team but will also drive the Company to continue executing our mission to save and improve the lives of patients with cancer.”. CAMBRIDGE, Mass.–(BUSINESS About Sesen Bio.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

JANUARY 24, 2022

where marijuana for recreational use has been legalized, the market has witnessed a dynamic shift of patients from traditional methods or medicine to opting to use marijuana for medical and other purposes. North America Legal Cannabis Number of clinical trials. For more information about this report visit [link].

Legalization 52

Legalization Supply Chain Chronic Pain Recreational 52

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Third-party clinical studies investigating oral psilocybin have reported compelling anti-depressant effects. II is a $287.5

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

DECEMBER 20, 2021

First Patient Expected to be Enrolled by Q2 of 2022. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., BERWYN, Pa.–(BUSINESS About Altasciences.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Cannabis Law Report

SEPTEMBER 20, 2021

Nanomerics”) to use Nanomeric’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children. For more information, please visit www.virpaxpharma.com. VRP324 is manufactured using high pressure homogenization and spray drying. Forward-Looking Statement.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

DECEMBER 23, 2021

However, regulations are constantly shifting beneath the feet of operators and their ability to serve patients depends on their capacity to navigate a changing landscape of governance. For more information about this report visit [link]. via inhalation of combusted flower). ResearchAndMarkets.com. Laura Wood, Senior Press Manager.

Pharmaceutical 96

Pharmaceutical Clinical Trials Research and Development Cannabinoids 96

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Peninsula Alternative Health

MAY 15, 2019

With clinical research developing rapidly in Israel and with the use of innovative technology we hope to have this information in the near future. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. These symptoms can be unbearable for both patients and their caregivers.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

The Cannigma

MARCH 12, 2021

But sometimes one unintended consequence of adult-use legalization is that the market no longer caters to medical patients. But also, you’re gaining a lot more technologies and scientific information just on how things work. But what do we do in the meantime? How do you address that? It’s germs that cause disease.”

Legalization 128

Legalization Patients Education Dispensary 128

Cannabis Law Report

AUGUST 2, 2021

(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. ” About The Study.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

DECEMBER 29, 2021

The company has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial and preparations to begin that trial are underway. Oravax is also preparing to commence clinical trials in Israel. About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain CBD 52

Cannabis Law Report

NOVEMBER 18, 2021

“Oravax has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial for its oral COVID-19 vaccine, and preparations to begin the trial are underway. Oravax is also preparing to commence clinical trials in Israel.”.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Chronic Pain 52